Pharmaceuticals

A recall of a vital pet arthritis drug due to glass fibers reveals a history of quality control failures, forcing a difficult reckoning for pet owners and vets.

With cash dwindling and a pivotal trial result looming after a recent failure, Vistagen brings a seasoned drug developer aboard to navigate the turbulence.

With Phase 3 results for Levosimendan imminent and its cash runway secured, Tenax Therapeutics faces a make-or-break moment in the PH-HFpEF space.

Amid production stoppages from extreme weather, nuclear operator Orano reveals a complex financial picture and a bold strategy for US expansion and diversification.

Karyopharm plans an accelerated FDA filing for its selinexor combo in myelofibrosis. The move hinges on a key surrogate endpoint and a race against competitors.

U.S. sugar demand remains surprisingly strong, but a perfect storm of health trends and weight-loss drugs like Ozempic threatens a $55 billion upheaval.

With $217M in the bank, SAB Biotherapeutics has silenced liquidity fears. Now, all eyes are on its novel T1D drug and the unproven promise of its cow-powered tech.

New patents in Europe and Australia grant Savara long-term protection for a vital new therapy, offering hope to patients with a rare, debilitating lung disease.

As Cellectar Biosciences preps its Q2 report, all eyes are on its cash runway and the immense promise of its targeted cancer therapy platform.

MIRA Pharmaceuticals moves two novel drug candidates closer to human trials, a key de-risking event for investors eyeing the massive pain and obesity markets.

Clinical research leader Novotech offers a strategic roadmap for biotech and pharma, aiming to de-risk and accelerate the complex world of autoimmune drug development.

As rising temperatures amplify India's public health risks, a new campaign tackles a persistent 'know-do gap' in dehydration treatment. But is consumer education enough?

Knight Therapeutics set a high bar in Q1. As it preps its Q2 results, we look at the strategy and market forces that will define its next chapter.

Regeneron's Q2 results reveal soaring sales from Dupixent and EYLEA HD, a pivotal pipeline, and a major financial reset with Sanofi. What's next?

AB2 Bio's partnership with Nippon Shinyaku for Tadekinig alfa signals a new era for ultra-rare pediatric care and highlights a savvy biotech financing strategy.

Lōkahi Therapeutics aims to turn 15 injections into one for its pain drug LT-100, a move that could transform patient care and unlock major commercial value.

Latigo Biotherapeutics' new drug LTG-001 shows superior, faster pain relief than Vicodin in a major trial, offering a potent new tool against the opioid crisis.

Skincare brand Valitic hit 2M customers, but the real story is how its e-commerce success provides the cash flow for parent Innocan Pharma's biotech ambitions.

While big chains falter, Good Neighbor Pharmacy, backed by a $300B giant, just won #1 in customer trust. Here’s the investment case for their model.